eBook - ePub
Heart Failure
An Essential Clinical Guide
Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler
This is a test
- 392 páginas
- English
- ePUB (apto para móviles)
- Disponible en iOS y Android
eBook - ePub
Heart Failure
An Essential Clinical Guide
Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler
Detalles del libro
Vista previa del libro
Índice
Citas
Información del libro
This "patient-oriented" book was written as a meeting ground for practicing clinicians, allied health professionals, and clinical researchers to provide a practical guide for the contemporary assessment and management of patients with heart failure and cardiomyopathy. It revolves around broad patient scenarios to elegantly (or expertly) guide diagnostic and management strategies. Combining the talents of over one-hundred experts in the field, the book also endeavors to challenge the reader with areas of current controversies and opportunities for clinical investigation with the goals of both orienting clinicians and stimulating their research passions.
Key Features
-
- Provides practical guidance based on real-life heart failure scenarios
-
- Discusses both acute and chronic care patient-oriented scenarios
-
- Covers up-to-date and novel concepts in heart failure
-
- Features the perspectives of current debates and controversies in heart failure
-
- Highlights the opportunities for research in this field
Preguntas frecuentes
¿Cómo cancelo mi suscripción?
¿Cómo descargo los libros?
Por el momento, todos nuestros libros ePub adaptables a dispositivos móviles se pueden descargar a través de la aplicación. La mayor parte de nuestros PDF también se puede descargar y ya estamos trabajando para que el resto también sea descargable. Obtén más información aquí.
¿En qué se diferencian los planes de precios?
Ambos planes te permiten acceder por completo a la biblioteca y a todas las funciones de Perlego. Las únicas diferencias son el precio y el período de suscripción: con el plan anual ahorrarás en torno a un 30 % en comparación con 12 meses de un plan mensual.
¿Qué es Perlego?
Somos un servicio de suscripción de libros de texto en línea que te permite acceder a toda una biblioteca en línea por menos de lo que cuesta un libro al mes. Con más de un millón de libros sobre más de 1000 categorías, ¡tenemos todo lo que necesitas! Obtén más información aquí.
¿Perlego ofrece la función de texto a voz?
Busca el símbolo de lectura en voz alta en tu próximo libro para ver si puedes escucharlo. La herramienta de lectura en voz alta lee el texto en voz alta por ti, resaltando el texto a medida que se lee. Puedes pausarla, acelerarla y ralentizarla. Obtén más información aquí.
¿Es Heart Failure un PDF/ePUB en línea?
Sí, puedes acceder a Heart Failure de Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler en formato PDF o ePUB, así como a otros libros populares de Medicine y Medical Theory, Practice & Reference. Tenemos más de un millón de libros disponibles en nuestro catálogo para que explores.
Información
Section III
Managing Chronic Heart Failure
DOI: 10.1201/9780429244544-12
Chapter 10 Outpatient Management of Stable Heart Failure with Reduced Ejection Fraction
Chapter 11 Exercise and Rehabilitation in Heart Failure
Chapter 12 The Patient with Ischemic Heart Failure
Chapter 13 The Non-Ischemic HEART FAILURE Patient
Chapter 14 Valvular Heart Disease and Heart Failure
Chapter 15 The Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)
Chapter 16 Heart Failure with Recovered Ejection Fraction (HFrecEF) and Heart Failure with Midrange Ejection Fraction (HFmrEF)
Chapter 17 The Advanced HEART FAILURE Patient
Chapter 18 Palliative Care and Advanced Directives in Heart Failure
Chapter 10
OUTPATIENT MANAGEMENT OF STABLE HEART FAILURE WITH REDUCED EJECTION FRACTION
Leah Reid, Jonathan Murrow, Kent Nilsson, and Catherine Marti
DOI: 10.1201/9780429244544-13
Introduction
Although therapies for HF with preserved ejection fraction (HFpEF) are lacking, there are many therapies available to patients with HF with reduced ejection fraction (HFrEF), regardless of symptomatology.1 Careful consideration should be taken at every encounter to evaluate not only volume status but also to optimize guideline-directed medical therapy as well as device therapy. In this chapter, we outline the current therapy available for outpatient management of HFrEF (Table 10.1).
| Starting Dose (mg) | Target Dose (mg) |
Beta-Blockers | ||
Bisoprolol | 1.25 daily | 10 daily |
Carvedilol | 3.125 b.i.d. | 25 b.i.d. for weight <85 kg and 50 b.i.d. for weight ≥85 kg |
Metoprolol succinate | 12.5–25 daily | 200 daily |
Angiotensin Receptor Neprilysin Inhibitors | ||
Sacubitril/valsartan | 24/26–49/51 b.i.d. | 97/103 b.i.d. |
Angiotensin-Converting Enzyme Inhibitors | ||
Captopril | 6.25 t.i.d. | 50 t.i.d. |
Enalapril | 2.5 b.i.d. | 10–20 b.i.d. |
Lisinopril | 2.5–5.0 daily | 20–40 daily |
Ramipril | 1.25 daily | 10 daily |
Angiotensin II Receptor Blockers | ||
Candesartan | 4–8 daily | 32 daily |
Losartan | 25–50 daily | 150 daily |
Valsartan | 40 b.i.d. | 160 b.i.d. |
Aldosterone Antagonists | ||
Eplerenone | 25 daily | 50 daily |
Spironolactone | 12.5–25 daily | 25–50 daily |
Sodium-Glucose Cotransporter-2 Inhibitors | ||
Dapagliflozin | 10 daily | 10 daily |
Empagliflozin | 10 daily | 10 daily |
Vasodilators | ||
Hydralazine | 25 t.i.d. | 75 t.i.d. |
Isosorbide dinitrate | 20 t.i.d. | 40 t.i.d. |
Fixed-dose combination isosorbide dinitrate/hydralazine | 20/37.5 (1 tab) t.i.d. | 2 tabs t.i.d. |
Ivabradine | ||
Ivabradine | 2.5–5 b.i.d. | Titrate to heart rate 50–60 beats/min. Maximum dose 7.5 b.i.d. |
Notes: Isosorbide mononitrate is not recommended by current guidelines, which consider either the fixed-dose combination or the separate combination of isosorbide dinitrate and hydralazine as appropriate guideline-directed therapies for heart failure. | ||
Abbreviations: b.i.d. = bis in die (twice daily); t.i.d. = ter in die (three times daily). | ||
Source: Reproduced with permission from: Maddox et al., J Am Coll Cardiol 2021;77:772–810. |
Beta-Blockers
Maladaptive activation of the sympathetic nervous system in HFrEF can lead to worsening congestion, malperfusion, and arrhythmias.2 Blockade of β-adrenergic receptors has proven in multiple clinical trials to reduce morbidity and mortality—specifically with metoprolol succinate and bisoprolol, which selectively block β-1-receptors, and with carvedilol, which selectively blocks α-1, β-1 and β-2 receptors.3
In the landmark Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), patients with HFrEF (ejection fraction [EF] ≤35%) and New York Heart Association (NYHA) class II–IV symptoms had a 34% relative risk reduction in all-cause mortality with bisoprolol therapy vs placebo.4 The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) and carvedilol trials likewise demonstrated reduced risk of death or HF hospitalization (Figure 10.1).5–7 To reduce morbidity and mortality, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Heart Failure Guidelines thus recommend using either bisoprolol, carvedilol, or sustained-release metoprolol succinate for all patients with current or prior symptoms of HFrEF unless contraindicated (class I, level of evidence [LOE]: A). Importantly, the benefit of β blockers is dose dependent, with lower achieved heart rates associated with improved outcomes, albeit this effect is mostly relevant to patients in sinus rhythm and not among those with atrial fibrillation.8 A network meta-analysis of 21 trials found a mortality benefit of β blockers vs p...